Quantcast
Home > Quotes > CERC

Cerecor Inc. Common Stock (CERC) Quote & Summary Data

CERC 
$3.21
*  
0.32
9.07%
Get CERC Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading CERC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
9.25
Today's High / Low
$ 3.53 / $ 3.2001
Share Volume
56,851
50 Day Avg. Daily Volume
165,862
Previous Close
$ 3.53
52 Week High / Low
$ 7.6499 / $ 2.71
Market Cap
137,730,648
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.17

Intraday Chart

Shares Traded

Share Volume:
56,851
50 Day Avg. Daily Volume:
165,862

Trading Range

The current last sale of $3.21 is 18.45% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.53 $ 7.6499
 Low: $ 3.2001 $ 2.71

Company Description (as filed with the SEC)

Cerecor Inc. (the Company or "Cerecor") is a fully integrated biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a robust pipeline of innovative therapies in neurology, pediatric healthcare, and orphan rare diseases. The Company's neurology pipeline is led by CERC-301, which is currently in a Phase I safety study for Neurogenic Orthostatic Hypotension ("nOH"). The Company is also developing two other neurological clinical and preclinical stage compounds. The Company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation ("CDGs") by means of substrate replacement therapy. The U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease designation ("RPDD") and Orphan Drug Designation ("ODD") to all three compounds.  ... More ...  



Risk Grade

Where does CERC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.53
Open Date:
Aug. 23, 2019
Close Price:
$ 3.21
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info